OA
MRTX

Omega Advisors’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Omega Advisors’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-100,000
Closed -$520K – 93
2017
Q1 		$520K Buy
+100,000
New +$548K 0.02% 83

Other funds holding MRTX

AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Omega Advisors's MRTX Position: Q2 2017 in Review

Omega Advisors sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q2 2017, closing a stake of 100,000 shares — an estimated $520K sold.

Omega Advisors first reported a position in MRTX in Q1 2017 and held it in 1 quarter. The position peaked at $520K in Q1 2017. 51 funds tracked by Wall St. Rank hold MRTX as of Q2 2017.

  • Omega Advisors reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q2 2017 after selling out during the quarter.
  • Omega Advisors sold 100,000 Mirati Therapeutics, Inc. Common Stock shares in Q2 2017, an estimated $520K.
  • Omega Advisors first reported a position in Mirati Therapeutics, Inc. Common Stock in Q1 2017 and held it in 1 quarter.
  • Omega Advisors's Mirati Therapeutics, Inc. Common Stock position peaked at $520K in Q1 2017.
  • 51 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q2 2017.

Based on Omega Advisors's 13F filing for Q2 2017, filed 14 Aug 2017.